Premium
Primary oral etoposide therapy in gestational trophoblastic disease: An update
Author(s) -
Wong L. C.,
Choo Y. C.,
Ma H. K.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860701)58:1<14::aid-cncr2820580104>3.0.co;2-r
Subject(s) - medicine , etoposide , gestational trophoblastic disease , choriocarcinoma , folinic acid , methotrexate , nausea , vomiting , chorioepithelioma , regimen , chemotherapy , hyperemesis gravidarum , oncology , gynecology , surgery , gestation , pregnancy , fluorouracil , biology , genetics
Sixty patients who developed persistent or metastatic gestational trophoblastic disease (GTD) received primary oral etoposide therapy (VP 16–213). Twelve patients had metastatic GTD. Fifty‐nine patients achieved biochemical remission. One patient had marked nausea and vomiting and the therapy was switched to a methotrexate/folinic acid regimen. Three patients developed relapse of GTD, giving a relapse rate of 5.1%. Etoposide is an active drug against choriocarcinoma. Its use should not be restricted to drug‐resistant GTD. Cancer 58:14–17, 1986.